Directly observed therapy for HIV/tuberculosis co-infection

Lancet Infectious Diseases

Volumn 4, Issue 3, 2004, Pages 137-138

  Lurie, Mark N ^a   Carter, E Jane ^b   Cohen, Jonathan ^b   Flanigan, Timothy P ^a  

^a BROWN UNIVERSITY   (United States)

^b MIRIAM HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; TUBERCULOSTATIC AGENT;

AFRICA; DIRECTLY OBSERVED THERAPY; FATALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; SHORT SURVEY; TUBERCULOSIS;

EID: 1442274997     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(04)00936-3     Document Type: Letter

References (16)

1. Kerr C. Drugs for HIV in South Africa. Lancet Infect Dis. 4:2004;2.
2. Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 338:1998;853-860.
3. Corbett E.L., Watt C.J., Walker N., et al. The growing burden of tuberculosis. Global trends and interactions with the HIV epidemic. Arch Intern Med. 163:2003;1009-1021.
4. Mukadi Y.D., Maher D., Harries A. Tuberculosis case fatality rates in high prevalence populations in sub-Saharan Africa. AIDS. 15:2001;143-152.
5. De Kock K.M., Wilkinson D. Tuberculosis control in resource poor countries: alternative strategies in the era of HIV. Lancet. 346:1995;675-677.
6. Whalen C., Okwera A., Johnson J., et al. Predictors of survival in human immunodeficiency virus infected patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 153:1996;1977-1981.
7. Elliott A.M., Halwindi B., Hayes R.J., et al. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans R Soc Trop Med Hyg. 89:1995;78-82.
8. Schluger N.W. Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients. Clin Infect Dis. 28:1999;130-135.
9. Harries A.D., Nyangulu D.S., Kangombe C., et al. Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba hospital, Malawi. Trans R Soc Trop Med Hyg. 92:1998;343-347.
10. Connolly C., Davies G.R., Wilkinson D. Impact of the human immunodeficiency virus epidemic on mortality among adults with tuberculosis in rural South Africa, 1991-1995. Int J Tuberc Lung Dis. 2:1998;919-925.
11. Weis W.E., Slocum P.C., Blais F.X., et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 330:1994;1179-1184.
12. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 3rd edn :2003;WHO, Geneva.
13. Fischl M, Castro J, Monroig R, et al. Impact of directly observed therapy on long-term outcomes in clinical trials. 8th Conference on Retroviruses and Opportunistic Infections; Chicago, IL; Feb 4-8, 2001.
14. Mitty J.A., Stone V.E., Sands M., Macalino G., Flanigan T. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis. 34:2002;984-990.
15. Jack C, Friedland G, Laloo U, et al. The START study: starting antiretroviral and tuberculosis therapy: a pilot study to integrate antiretroviral therapy into existing tuberculosis directly observed therapy program in a resource limited setting, 10th Conference on Retroviruses and Opportunistic Infections; Boston, MA; Feb 10-14, 2003, Abstract 783.
16. Gebrekristos H, Mthethwa N, Abdool Karim Q, Lurie M. Knowledge and acceptability of HAART in tuberculosis patients attending a primary care clinic in KwaZulu-Natal, South African AIDS Conference; Durban; Aug 3-6, 2003.